Tango Therapeutics, Inc. · NASDAQ:TNGX
Tango Therapeutics — SPAC Merger (April 2021)
14 slides from Tango Therapeutics's SPAC merger presentation, Apr 14, 2021
Slide 1: Unmasking vulnerabilities in cancer to deliver the next generation of precision medicines
APRIL 2021 Unmasking vulnerabilities in cancer to deliver the next generation of precision medicines
Slide 2: Disclaimer
Confidential | 2 Disclaimer This presentation (“Presentation”) is for informational purposes only to assist interested parties in making their own evalua tio n with respect to the proposed business combination (the “Business Combination”) between BCTG Acquisition Corp. (“BCTG”) and Tango Therapeutic
Slide 3: Disclaimer (continued)
Confidential | 3 Disclaimer (continued) Certain information contained in this Presentation relates to or is based on studies, publications, surveys and Tango’s own i nte rnal estimates and research. In addition, all of the market data included in this Presentation involve a number of assumptions and
Slide 4: Risk factors
Confidential | 4 Risk factors • We are a biopharmaceutical company with a limited operating history and have not generated any revenue to date from drug sale s, and may never become profitable. • We have incurred significant operating losses in recent periods and anticipate that we will incur contin
Slide 5: Investment highlights
Confidential | 5 Investment highlights Precision oncology company based on synthetic lethality, combining discovery and clinical development in the same genetic context Expanding oncology target space into tumor suppressor gene loss with a productive, state - of - the - art discovery platform Pipe
Slide 6: Tumor suppressor gene loss is a large oncology target space
Confidential | 6 Tumor suppressor gene loss is a large oncology target space SYNTHETIC LETHALITY • Currently the only way to target tumor suppressor gene loss • Drugs are selectively active in cancer cells and relatively inert in normal cells • PARP inhibitors are the clinical proof - of - concept T
Slide 7: Tango leadership, board of directors and investors
Confidential | 7 BOARD OF DIRECTORS LEADERSHIP Cary Pfeffer, MD Mike Pellini, MD Reid Huber, PhD John Maxwell, PhD Chemistry Heather DiBenedetto, MS Development Operations Barbara Weber, MD CEO Alan Huang, PhD CSO Daniella Beckman CFO Charles Davis, PhD Pharmaceutical Sciences Jannik Andersen, PhD B
Slide 8: Tango pipeline and anticipated milestones
Confidential | 8 PROGRAM PATIENTS DISCOVERY LEAD OPTIMIZATION IND - ENABLING CLINICAL ANTICIPATED MILESTONES Ph I/II Ph III PRMT5 TNG908 MTAP - del cancers IND filing 4Q 2021 USP1 BRCA1 - mut cancers IND filing 2022 TARGET 3 STK11 - mut lung cancer IND filing 2023 TARGET 4* Solid tumors IND filing 2
Slide 9: TNG908 is an MTA-cooperative PRMT5 inhibitor
Confidential | 9 MTAP DELETION FREQUENCY TCGA PanCancer Atlas TNG908 is an MTA - cooperative PRMT5 inhibitor with 15X selectivity for MTAP - deleted cancer cells HCT116 (colon) MTAP deletion MTAP wild - type TNG908
Slide 10: PRMT5 first-in-human study in solid tumors with MTAP deletion
Confidential | 10 1H 2022 Planned start of proposed clinical study Bladder, lung and cholangiocarcinoma (squamous and non - squamous) n ~ 20 each 15 - 30% MTAP - null Malignant peripheral nerve sheath tumors n ~ 20 30 - 50% MTAP - null Accelerated approval option Histology - agnostic “bucket” (enric
Slide 11: USP1 and BRCA1 are a synthetic lethal pair
Confidential | 11 Control (DMSO) USP1i (0.5 µM) BRCA1 mut BRCA1 WT UWB1.289 MDA - MB - 436 HCC1954 AU565 • USP1 is a de - ubiquitinating enzyme (DUB) that is synthetic lethal with BRCA1 • Some BRCA1 WT lung cancer cell lines are sensitive to USP1 inhibition, patient selection marker being evaluated
Slide 12: Target 3 inhibition reverses immune evasion in STK11 mutant tumors
Confidential | 12 Target 3 tool compound in STK11 mutant MC38 mice Control a - PD1 DAY 18 Treatment stopped DAY 24 No detectable tumor in 9/10 mice Days post treatment initiation Tumor Volume (mm 3 ) 2500 2000 1500 1000 500 0 0 5 10 15 20 25 Target 3 inhibition reverses immune evasion in STK11 mutan
Slide 13: Pipeline milestones and pro forma cash
Confidential | 13 Pipeline PRMT5 Multiple key milestones achievable through 2H 2024 Clinical proof - of - concept data in multiple tumor types Enrollment for accelerated approval in rare tumor type (MPNST) Phase I clinical trial complete, registrational studies in start up Compre hensive pro
Slide 14: Tango Therapeutics
By) TANGO therapeutics